+

WO2004005262A8 - Nouveaux antagonistes des recepteurs du neuropeptide y y5 - Google Patents

Nouveaux antagonistes des recepteurs du neuropeptide y y5

Info

Publication number
WO2004005262A8
WO2004005262A8 PCT/US2003/020489 US0320489W WO2004005262A8 WO 2004005262 A8 WO2004005262 A8 WO 2004005262A8 US 0320489 W US0320489 W US 0320489W WO 2004005262 A8 WO2004005262 A8 WO 2004005262A8
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
npy
methods
well
neuropeptide
Prior art date
Application number
PCT/US2003/020489
Other languages
English (en)
Other versions
WO2004005262A2 (fr
WO2004005262A3 (fr
Inventor
Andrew W Stamford
Yusheng Wu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to JP2004519682A priority Critical patent/JP4498133B2/ja
Priority to MXPA05000200A priority patent/MXPA05000200A/es
Priority to AU2003251739A priority patent/AU2003251739A1/en
Priority to EP03763043A priority patent/EP1601666A2/fr
Priority to CA002490470A priority patent/CA2490470A1/fr
Publication of WO2004005262A2 publication Critical patent/WO2004005262A2/fr
Publication of WO2004005262A3 publication Critical patent/WO2004005262A3/fr
Publication of WO2004005262A8 publication Critical patent/WO2004005262A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention se rapporte à des composés qui constituent de nouveaux antagonistes des récepteurs du neuropeptide Y (NPY) Y5, ainsi qu'à des procédés pour préparer ces composés. Dans un autre mode de réalisation, cette invention concerne des compositions pharmaceutiques comprenant de tels antagonistes des récepteurs du NPY Y5, ainsi que des procédés d'utilisation de ces compositions pour traiter l'obésité, les troubles du métabolisme, les troubles de l'alimentation tels que l'hyperphagie, et le diabète.
PCT/US2003/020489 2002-07-02 2003-06-30 Nouveaux antagonistes des recepteurs du neuropeptide y y5 WO2004005262A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2004519682A JP4498133B2 (ja) 2002-07-02 2003-06-30 新規神経ペプチドｙｙ５レセプターアンタゴニスト
MXPA05000200A MXPA05000200A (es) 2002-07-02 2003-06-30 Nuevos antagonistas del receptor neuropeptido y y5.
AU2003251739A AU2003251739A1 (en) 2002-07-02 2003-06-30 New neuropeptide y y5 receptor antagonists
EP03763043A EP1601666A2 (fr) 2002-07-02 2003-06-30 Antagonistes de recepteur de neuropeptide y y5
CA002490470A CA2490470A1 (fr) 2002-07-02 2003-06-30 Antagonistes du recepteur y y5 de neuropeptide pyrazole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39332702P 2002-07-02 2002-07-02
US60/393,327 2002-07-02

Publications (3)

Publication Number Publication Date
WO2004005262A2 WO2004005262A2 (fr) 2004-01-15
WO2004005262A3 WO2004005262A3 (fr) 2004-04-15
WO2004005262A8 true WO2004005262A8 (fr) 2005-04-28

Family

ID=30115567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020489 WO2004005262A2 (fr) 2002-07-02 2003-06-30 Nouveaux antagonistes des recepteurs du neuropeptide y y5

Country Status (8)

Country Link
US (1) US7157472B2 (fr)
EP (1) EP1601666A2 (fr)
JP (1) JP4498133B2 (fr)
CN (1) CN1678608A (fr)
AU (1) AU2003251739A1 (fr)
CA (1) CA2490470A1 (fr)
MX (1) MXPA05000200A (fr)
WO (1) WO2004005262A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907577A2 (pt) 2008-02-22 2015-07-21 Hoffmann La Roche Moduladores para amiloide beta
MX2011003246A (es) 2008-10-09 2011-04-21 Hoffmann La Roche Moduladores de beta amiloide.
MX2011004954A (es) * 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
ES2615738T3 (es) 2011-05-13 2017-06-08 Array Biopharma, Inc. Compuestos de pirrolidinil urea, pirrolidinil tiourea y pirrolidinil guanidina como inhibidores de trkA quinasa
ES2664331T3 (es) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
WO2014078372A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de pyrazolylurée, d'urée, de thiourée, de guanidine et de cyanoguianidine en tant qu'inhibiteurs de la trka kinase
WO2014078331A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014078325A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase
WO2014078454A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de thio-urée, guanidine, cynoguanidine et d'urée bicycliques utiles pour le traitement de la douleur
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US20160304466A1 (en) * 2013-12-04 2016-10-20 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
WO2015089800A1 (fr) 2013-12-19 2015-06-25 Eli Lilly And Company Composés fluorophényl-pyrazole
ES2746530T3 (es) 2014-05-15 2020-03-06 Array Biopharma Inc 1-((3S,4R)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidín-3-il)-3-(4-metil-3-(2-metilpirimidín-5-il)-1-fenil-1H-pirazol-5- il)urea como un inhibidor de TrkA cinasa
KR101689382B1 (ko) 2015-05-11 2016-12-23 코오롱인더스트리 주식회사 이동통신단말 착신 알림 기능을 구비한 스마트 백 및 이를 활용한 착신 알림 방법
WO2017114377A1 (fr) * 2015-12-29 2017-07-06 四川海思科制药有限公司 Dérivé d'un composé benzyle hétérocyclique et application pharmaceutique correspondante
CN114206911A (zh) * 2019-05-30 2022-03-18 加利福尼亚大学董事会 用轴突导向因子-1化合物治疗高脂血疾患的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
NZ201395A (en) 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4616014A (en) 1981-10-22 1986-10-07 Fujisawa Pharmaceutical Co., Ltd. Triazine derivatives, and pharmaceutical compositions comprising the same
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
DE3601196A1 (de) 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
CA2046628A1 (fr) 1989-02-08 1990-08-09 Dee W. Brooks 4-hydroxythiazoles comme inhibiteurs de la 5-lipoxygenase
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US5792138A (en) 1996-02-22 1998-08-11 Apollo Camera, Llc Cordless bipolar electrocautery unit with automatic power control
WO1998024768A1 (fr) * 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Nouveaux derives d'uree
US6166038A (en) * 1996-12-13 2000-12-26 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
CA2350714A1 (fr) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines en tant qu'antagonistes du recepteur y5
US6291476B1 (en) * 1999-05-12 2001-09-18 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
JP4226326B2 (ja) 2000-12-21 2009-02-18 シェーリング コーポレイション ヘテロアリール尿素神経ペプチドｙｙ５レセプターアンタゴニスト
EP1451160B1 (fr) * 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides pour utilisation dans le traitement de la douleur

Also Published As

Publication number Publication date
CA2490470A1 (fr) 2004-01-15
US20040034008A1 (en) 2004-02-19
CN1678608A (zh) 2005-10-05
JP4498133B2 (ja) 2010-07-07
WO2004005262A2 (fr) 2004-01-15
WO2004005262A3 (fr) 2004-04-15
AU2003251739A8 (en) 2004-01-23
MXPA05000200A (es) 2005-06-06
JP2005532392A (ja) 2005-10-27
EP1601666A2 (fr) 2005-12-07
AU2003251739A1 (en) 2004-01-23
US7157472B2 (en) 2007-01-02

Similar Documents

Publication Publication Date Title
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2004005262A8 (fr) Nouveaux antagonistes des recepteurs du neuropeptide y y5
WO2003045918A8 (fr) Antagonistes de la mch à base de pipéridine pour le traitement de l'obésité et des troubles liés au système nerveux central (cns)
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2003028641A3 (fr) Antagonistes du recepteur de la mch
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2007120284A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2006044504A8 (fr) Antagonistes aux récepteurs de cgrp
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2007025069A3 (fr) Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
WO2006086488A3 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
WO2006014618A3 (fr) Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2007061763A3 (fr) Antagonistes des recepteurs de l’indole orexine
WO2007111864A3 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
WO2007079214A3 (fr) Antagonistes du recepteur de la prokineticine 2
WO2007079163A3 (fr) Antagonistes du recepteur de la prokineticine 1
WO2007114855A3 (fr) Antagonistes du récepteur du glucagon, préparation et utilisations thérapeutiques
EP1398029A8 (fr) Derivés de pyrazole,substitués en position 3 ayant une affinité envers le NR3B1 récepteur
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
WO2006047196A3 (fr) Antagonistes de recepteurs cgrp
WO2006023852A3 (fr) Modulateurs des recepteurs muscariniques
WO2005082893A3 (fr) Antagonistes du recepteur d'histamine h3, leur preparation et leurs utilisations therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2490470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004519682

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000200

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003763043

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038206277

Country of ref document: CN

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 03/2004 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II)) FOR ALL DESIGNATIONS EXCEPT US."; ADD "DECLARATION UNDER RULE 4.17: - AS TO THE APPLICANT S ENTITLEMENT TO CLAIM THE PRIORITY OF THE EARLIER APPLICATION (RULE 4.17(III)) FOR ALL DESIGNATIONS."

WWP Wipo information: published in national office

Ref document number: 2003763043

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载